The FDA has released an updated safety review that links Actos use to an increased risk of bladder cancer. This warning was first made public in 2010, added to labels of pioglitazone-containing medicines in 2011, and was further confirmed through additional studies reviewed by the FDA in late 2016.
About Actos
Actos is a medication approved to improve blood sugar control in adults with type 2 diabetes. Pioglitazone is intended to increase the body’s sensitivity to insulin, which is a natural hormone that helps control blood sugar levels.
By reviewing more than four epidemiological studies assessing the risk of bladder cancer with Actos use, the FDA concluded that pioglitazone may be associated with an increased risk in urinary bladder cancer.
Symptoms of bladder cancer may include, but aren’t limited to:
- Blood or red color in urine
- New or worsening urge to urinate
- Pain when urinating
Take Action
At Foster & Houston, we’ve been helping victims of bladder cancer caused by Actos for years. If you or a loved one has taken Actos, it’s important to be aware of your rights. You can inquire about a potential Actos lawsuit by calling (800) 943-3071 or by visiting our website.
Sources: FDA
Additional Actos Resources:
- Blog: New Report Supports Claim That Actos Raises Bladder Cancer Risk
- Blog: $2.2 Billion Offered to Settle Actos Lawsuits
- Blog: Actos Linked to Bladder Cancer: What You Need to Know
- How to Know if You Have an Actos Case